FDA Proposes Status Reports, Web Postings For Postmarket Studies
This article was originally published in The Gray Sheet
Executive Summary
Device firms should submit interim status reports on mandated post-approval studies to FDA every six months for a study's first two years and annually thereafter, a newly released draft guidance states
You may also be interested in...
Compliance With Post-Approval Commitments Goes Public On CDRH Web Site
A Web site that will publicly display the status of FDA-required post-approval medical device studies will be operational within weeks, according to Steven Chasin, deputy director of the postmarket surveillance division at CDRH's Office of Surveillance & Biometrics
Compliance With Post-Approval Commitments Goes Public On CDRH Web Site
A Web site that will publicly display the status of FDA-required post-approval medical device studies will be operational within weeks, according to Steven Chasin, deputy director of the postmarket surveillance division at CDRH's Office of Surveillance & Biometrics
Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data